Bank on Houston

acActos Lawsuit: There is a very close relationship between survival of an individual and the stage of bladder cancer at diagnosis. For superficial disease, five year survival rates are greater than 90%. Once the cancer has spread into the bladder muscle and beyond, survival is markedly reduced. Five year survival in those with T2 disease (tumor invading superficial bladder muscle) is 60-75%, T3 disease (tumor invading deep muscle) 36-58%, and for those with T4 disease (tumor invading surrounding organs) or with node positive disease, 4-35%.’ With distant (metastatic) spread, survival at five years is less than 5%.

Most individuals with bladder cancer will undergo an initial removal of their bladder tumor by biopsy or for larger tumors by resection of their tumor via a resectoscope. For complete details see Chapter 8. Once this tumor is removed, the pathologist will determine and report on the extent of tumor invasion into the wall of the bladder. If the tumor has grown into the prostate, tissue removal via the resectoscope from this location will also be reviewed and reported pathologically. This pathologic diagnosis determines the initial stage of the cancer.

When dealing with large tumors after the initial cancer resection, your urologist may do a manual exam under anesthesia. By pressing deeply on the pelvis, the urologist may be able to palpate the tumor and assess its possible spread beyond the bladder. With modern technology and the availability of the CT scan, the manual exam is now of less importance. The CT scan can often visualize a thickened or distorted bladder wall, indicating the possibility of tumor involvement or extension through the wall. More importantly, it can determine spread to adjacent organs or lymph node involvement. Distant spread into the abdomen or beyond may also be seen. Other studies, such as the Bone Scan or Chest X ray can assess the presence and extent of metastatic diseases, MRI can be used for those with limited kidney function that cannot have a CT scan. More recently, Positron Emission Tomography (PET) scan has become available. This study can sometimes locate small deposits of metastatic disease not visible on CT or MRI scan.

Our use of the term or terms Actos Lawsuit is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

Actos Lawsuit

Actos Lawsuit: A small amount of microscopic hematuria in an individual without symptoms (asymptomatic microscopic hematuria) can be found in many healthy individuals. It has been estimated that up to 10% of the population has asymptomatic microscopic hematuria. In brief, the older you are (generally over the age of 40), the more risk factors you have (smoking, occupational exposure), and the more red blood cells present, the more likely serious pathology (disease of the urinary tract including bladder cancer) will be found. If you have persistent microscopic hematuria without a known cause, a urologic assessment is recommended.

When assessment for hematuria is required, the entire urinary tract is evaluated. This is accomplished via imaging studies (X ray or ultrasound), cystoscopy (visual inspection of the bladder), and possibly cytology (urine test for cancer cells). There are multiple causes for blood in the urine, including the possibility of kidney disease, kidney, ureteral or bladder stones, infection, or enlargement of the prostate. Approximately twenty percent of patients with bladder cancer will complain of irritative voiding symptoms. These symptoms include urinary urgency (a need to rush to the bathroom), burning and urinary frequency. These same symptoms are present in other urologic conditions such as infection, bladder instability and prostatic enlargement in men. These symptoms are most commonly associated with a diffuse superficial form of transitional cell cancer of the bladder called CIS (carcinoma in situ). Unfortunately for some, their diagnosis may be delayed since these symptoms are present in so many other diseases.

Actos Lawsuit

Actos Lawsuit: T2 lesions: tumors in this stage have superficially invaded the muscularis propria, the thick muscle layer of the bladder. These tumors usually are high grade. Although they may be amenable to local therapy, they have a high rate of further invasion and are at high risk for developing metastatic disease. T3 lesions: these tumors are almost always high grade, nodular, and very aggressive. Unfortunately, many may actually be under­staged tumors with the cancer already spread beyond the confines of the bladder. When an individual develops muscle invasive bladder cancer, major intervention is required to prevent spread and save the life of the individual. T4 lesions: high grade invasive, aggressive tumors which have invaded adjacent organs. Many of these have also spread to distant parts of the body (are understaged) and are incurable.

A number of other factors may be utilized to help predict the likelihood of recurrence and progression of an individual’s bladder cancer after treatment. Tumor size: There generally is little difference in the recurrence rates of small tumors (tumors approximately 1-3 cm in size or V2-I Vi inches in size). As tumors grow to mid size and larger, it is generally believed that recurrence rates are increased. Tumor Configuration: More important than the size alone is the actual appearance of the tumor. Tumors that are papillary in appearance usually have a better prognosis than tumors that are solid (sessile or nodular). Multifocality: When multiple tumors are present, scattered over various sites, the prognosis is worsened. If CIS is present in conjunction with bladder tumors, the rate of recurrence and progression is markedly worsened. Having multiple sites affected represents a widespread abnormal urothelium with an increased risk of future disease.

Our use of the term or terms Actos Lawsuit is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

Actos Lawsuit